{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:39:08Z","timestamp":1793093948933,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate if provider characteristics affect attitude toward carbonic anhydrase inhibitors (CAI) prescription for patients with history of sulfonamide antibiotic (SA) hypersensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A survey querying providers\u2019 attitudes toward CAI prescription in hypothetical patients with prior SA hypersensitivity was distributed to four ophthalmology and optometry organizations. Logistic regression was used to assess the relationship between avoiding CAI and profession, specialty, organizational affiliation, and years in practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 250 respondents, 27% and 52% would avoid topical and oral CAI, respectively, in patients with prior SA rash and\/or urticaria. &gt;90% would avoid oral CAI in patients with prior severe SA hypersensitivity. Respondents with &gt;10 years in practice were more likely to avoid oral CAI in patients with prior SA rash and\/or urticaria than those with \u226410 (OR 2.27, <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Respondents affiliated with non-glaucoma organizations were more likely to avoid oral CAI in patients with prior SA rash and\/or urticaria than those affiliated with glaucoma organizations (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). Providers without glaucoma training were more likely to avoid topical CAI in patients with prior SA rash and\/or urticaria (<jats:italic>p<\/jats:italic>\u2009=\u20090.004) and anaphylaxis (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) than glaucoma-trained providers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Despite no supporting evidence, a significant number of respondents would avoid CAI in patients with prior SA hypersensitivity. Respondents without glaucoma training, no affiliation with a glaucoma organization, and &gt;10 years in practice are more likely to avoid CAI in patients with type I SA hypersensitivity. Providers should be informed of the low cross-reactivity risk between CAI and SA so more patients may benefit from these drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03674-9","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T14:12:41Z","timestamp":1739628761000},"page":"1495-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prescribing carbonic anhydrase inhibitors to patients with \u201csulfa\u201d antibiotics allergy: do we dare?"],"prefix":"10.1038","volume":"39","author":[{"given":"Raquel","family":"Quintanilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9204-856X","authenticated-orcid":false,"given":"Arjun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4827-5014","authenticated-orcid":false,"given":"Ta Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hodapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McSoley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-4196","authenticated-orcid":false,"given":"Alana","family":"Grajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bitrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"3674_CR1","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/all.12881","volume":"71","author":"L Zhou","year":"2016","unstructured":"Zhou L, Dhopeshwarkar N, Blumenthal KG, et al. Drug allergies documented in electronic health records of a large healthcare system. Allergy. 2016;71:1305\u201313. https:\/\/doi.org\/10.1111\/all.12881.","journal-title":"Allergy"},{"key":"3674_CR2","doi-asserted-by":"publisher","first-page":"778.e1","DOI":"10.1016\/j.amjmed.2009.01.034","volume":"122","author":"E Macy","year":"2009","unstructured":"Macy E, Poon K-Y T. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122:778.e1\u2013778.e7. https:\/\/doi.org\/10.1016\/j.amjmed.2009.01.034.","journal-title":"Am J Med"},{"key":"3674_CR3","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/archinte.160.18.2819","volume":"160","author":"CE Lee","year":"2000","unstructured":"Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. 2000;160:2819\u201322. https:\/\/doi.org\/10.1001\/archinte.160.18.2819.","journal-title":"Arch Intern Med"},{"key":"3674_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/pai.12273","volume":"25","author":"S Kuyucu","year":"2014","unstructured":"Kuyucu S, Mori F, Atanaskovic-Markovic M, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive review. Pediatr Allergy Immunol. 2014;25:534\u201343. https:\/\/doi.org\/10.1111\/pai.12273.","journal-title":"Pediatr Allergy Immunol"},{"key":"3674_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40521-017-0128-2","volume":"4","author":"ER Gomes","year":"2017","unstructured":"Gomes ER, Kuyucu S. Epidemiology and risk factors in drug hypersensitivity reactions. Curr Treat Options Allergy. 2017;4:239\u201357. https:\/\/doi.org\/10.1007\/s40521-017-0128-2.","journal-title":"Curr Treat Options Allergy"},{"key":"3674_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/pds.4134","volume":"26","author":"KW McConeghy","year":"2017","unstructured":"McConeghy KW, Caffrey AR, Morrill HJ, Trivedi AN, LaPlante KL. Are non-allergic drug reactions commonly documented as medication \u201callergies\u201d? A national cohort of Veterans\u2019 admissions from 2000 to 2014. Pharmacoepidemiol Drug Saf. 2017;26:472\u20136. https:\/\/doi.org\/10.1002\/pds.4134.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3674_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaci.2003.11.030","volume":"113","author":"JPH Depta","year":"2004","unstructured":"Depta JPH, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ. Drug interaction with T-cell receptors. J Allergy Clin Immunol. 2004;113:519\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2003.11.030.","journal-title":"J Allergy Clin Immunol"},{"key":"3674_CR8","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/0161-5890(88)90050-8","volume":"25","author":"DG Harle","year":"1988","unstructured":"Harle DG, Baldo BA, Wells JV. Drugs as allergens: Detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol. 1988;25:1347\u201354. https:\/\/doi.org\/10.1016\/0161-5890(88)90050-8.","journal-title":"Mol Immunol"},{"key":"3674_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00002018-200124040-00001","volume":"24","author":"S Knowles","year":"2001","unstructured":"Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Drug Saf. 2001;24:239\u201347. https:\/\/doi.org\/10.2165\/00002018-200124040-00001.","journal-title":"Drug Saf"},{"key":"3674_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/0091-6749(94)90120-1","volume":"94","author":"CV Meekins","year":"1994","unstructured":"Meekins CV, Sullivan TJ, Gruchalla RS. Immunochemical analysis of sulfonamide drug allergy: Identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol. 1994;94:1017\u201324. https:\/\/doi.org\/10.1016\/0091-6749(94)90120-1.","journal-title":"J Allergy Clin Immunol"},{"key":"3674_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1592\/phco.24.9.856.36106","volume":"24","author":"CC Brackett","year":"2004","unstructured":"Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24:856\u201370. https:\/\/doi.org\/10.1592\/phco.24.9.856.36106.","journal-title":"Pharmacotherapy"},{"key":"3674_CR12","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2146\/ajhp120291","volume":"70","author":"NR Wulf","year":"2013","unstructured":"Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm. 2013;70:1483\u201394. https:\/\/doi.org\/10.2146\/ajhp120291.","journal-title":"Am J Health Syst Pharm"},{"key":"3674_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-018-0791-9","volume":"18","author":"JM Dorn","year":"2018","unstructured":"Dorn JM, Alpern M, McNulty C, Volcheck GW. Sulfonamide Drug Allergy. Curr Allergy Asthma Rep. 2018;18:1\u201310. https:\/\/doi.org\/10.1007\/s11882-018-0791-9.","journal-title":"Curr Allergy Asthma Rep"},{"key":"3674_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1345\/aph.1E350","volume":"39","author":"KK Johnson","year":"2005","unstructured":"Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? Ann Pharmacother. 2005;39:290\u2013301. https:\/\/doi.org\/10.1345\/aph.1E350.","journal-title":"Ann Pharmacother"},{"key":"3674_CR15","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/nejmoa022963","volume":"349","author":"B Strom","year":"2003","unstructured":"Strom B, Schinnar R, Apter J, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628\u201335. https:\/\/doi.org\/10.1056\/nejmoa022963.","journal-title":"N Engl J Med"},{"key":"3674_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ajo.2004.02.019","volume":"138","author":"AG Lee","year":"2004","unstructured":"Lee AG, Anderson R, Kardon RH, Wall M. Presumed \u201csulfa allergy\u201d in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol. 2004;138:114\u20138. https:\/\/doi.org\/10.1016\/j.ajo.2004.02.019.","journal-title":"Am J Ophthalmol"},{"key":"3674_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1592\/phco.26.4.551","volume":"26","author":"BA Hemstreet","year":"2006","unstructured":"Hemstreet BA, Page RL. Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients. Pharmacotherapy. 2006;26:551\u20137. https:\/\/doi.org\/10.1592\/phco.26.4.551.","journal-title":"Pharmacotherapy"},{"key":"3674_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1089\/jop.2012.0123","volume":"29","author":"GB Guedes","year":"2013","unstructured":"Guedes GB, Karan A, Mayer HR, Shields MB. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors. J Ocul Pharmacol Ther. 2013;29:456\u201361. https:\/\/doi.org\/10.1089\/jop.2012.0123.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3674_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jcpt.12048","volume":"38","author":"S Ghimire","year":"2013","unstructured":"Ghimire S, Kyung E, Lee JH, Kim JW, Kang W, Kim E. An evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications. J Clin Pharm Ther. 2013;38:196\u2013202. https:\/\/doi.org\/10.1111\/jcpt.12048.","journal-title":"J Clin Pharm Ther"},{"key":"3674_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/s-0038-1637943","volume":"09","author":"EA Balas","year":"2000","unstructured":"Balas EA, Boren SA. Managing clinical knowledge for health care improvement. Yearb Med Inform. 2000;09:65\u201370. https:\/\/doi.org\/10.1055\/s-0038-1637943.","journal-title":"Yearb Med Inform"},{"key":"3674_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/pharmacy7030132","volume":"7","author":"A Giles","year":"2019","unstructured":"Giles A, Foushee J, Lantz E, Gumina G. Sulfonamide allergies. Pharmacy. 2019;7:132 https:\/\/doi.org\/10.3390\/pharmacy7030132.","journal-title":"Pharmacy"},{"key":"3674_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40123-018-0136-8","volume":"7","author":"TJ Shah","year":"2018","unstructured":"Shah TJ, Moshirfar M, Hoopes PC. Doctor, i have a sulfa allergy\u201d: clarifying the Myths of cross-reactivity. Ophthalmol Ther. 2018;7:211\u20135. https:\/\/doi.org\/10.1007\/s40123-018-0136-8.","journal-title":"Ophthalmol Ther"},{"key":"3674_CR23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/all.13380","volume":"73","author":"M Worm","year":"2018","unstructured":"Worm M, Francuzik W, Renaudin JM, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the European anaphylaxis registry. Allergy. 2018;73:1322\u201330. https:\/\/doi.org\/10.1111\/all.13380.","journal-title":"Allergy"},{"key":"3674_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11096-010-9389-6","volume":"32","author":"GC Wall","year":"2010","unstructured":"Wall GC, DeWitt JE, Haack S, Fornoff A, Eastman DK, Koenigsfeld CF. Knowledge and attitudes of American pharmacists concerning sulfonamide allergy cross-reactivity. Pharm World Sci. 2010;32:343\u20136. https:\/\/doi.org\/10.1007\/s11096-010-9389-6.","journal-title":"Pharm World Sci"},{"key":"3674_CR25","first-page":"558","volume":"6","author":"V Mosely","year":"1955","unstructured":"Mosely V, Baroody NB. Some observations on the use of acetazolamide (\u201cDiamox\u201d) as an oral diuretic in various edematous states and in uremia with hyperkalemia. Am Pract Dig Treat. 1955;6:558\u201366.","journal-title":"Am Pract Dig Treat"},{"key":"3674_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/archopht.1990.01070070020005","volume":"108","author":"JG Stock","year":"1990","unstructured":"Stock JG. Sulfonamide hypersensitivity and acetazolamide. Arch Ophthalmol. 1990;108:634 https:\/\/doi.org\/10.1001\/archopht.1990.01070070020005.","journal-title":"Arch Ophthalmol"},{"key":"3674_CR27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/bjo.51.5.348","volume":"51","author":"A Kristinsson","year":"1967","unstructured":"Kristinsson A. Fatal reaction to acetazolamide. Br J Ophthalmol. 1967;51:348\u20139. https:\/\/doi.org\/10.1136\/bjo.51.5.348.","journal-title":"Br J Ophthalmol"},{"key":"3674_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0002-9394(14)71807-0","volume":"114","author":"J Peralta","year":"1992","unstructured":"Peralta J, Abelairas J, Fern\u00e1ndez-Guardiola J. Anaphylactic shock and death after oral intake of acetazolamide. Am J Ophthalmol. 1992;114:367 https:\/\/doi.org\/10.1016\/S0002-9394(14)71807-0.","journal-title":"Am J Ophthalmol"},{"key":"3674_CR29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1136\/bjo.82.5.584a","volume":"82","author":"N Tzanakis","year":"1998","unstructured":"Tzanakis N, Metzidaki G, Thermos K, Spyraki C, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide. Br J Ophthalmol. 1998;82:588 https:\/\/doi.org\/10.1136\/bjo.82.5.584a.","journal-title":"Br J Ophthalmol"},{"key":"3674_CR30","first-page":"1228","volume":"44","author":"LJ Gerhards","year":"2000","unstructured":"Gerhards LJ, van Arnhem AC, Holman ND, Nossent GD. Fatale anafylactische reactie na inname van acetazolamide (Diamox) wegens glaucoom [Fatal anaphylactic reaction after oral acetazolamide (diamox) for glaucoma]. Ned Tijdschr Geneeskd. 2000;44:1228\u201330.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"3674_CR31","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/archneurol.2011.2723","volume":"69","author":"D Platt","year":"2012","unstructured":"Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol. 2012;69:527\u20139. https:\/\/doi.org\/10.1001\/archneurol.2011.2723.","journal-title":"Arch Neurol"},{"key":"3674_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.0105-1873.2004.00274.x","volume":"51","author":"P Tornero","year":"2004","unstructured":"Tornero P, de Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51:57\u201362. https:\/\/doi.org\/10.1111\/j.0105-1873.2004.00274.x.","journal-title":"Contact Dermatitis"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03674-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03674-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03674-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:25:29Z","timestamp":1747657529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03674-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3674"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03674-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}